Story · Medicine & Biotech
FDA Slaps New Safety Warning on GLP-1 Drugs
21 outlets · first reported by FDA MedWatch Safety Alerts 2d ago · latest 11h ago · 57 hours of coverage · 3 countries
Coverage, in order
-
2d agoMedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication
-
2d agoFDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
-
2d ago
STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye conditionThe Food and Drug Administration on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors of the risk. The condition, called non-arteritic anterior ischemic optic neuropathy, or NAION, is sometimes…
-
2d agoU.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.
-
2d ago
FDA Slaps New Safety Warning on GLP-1 Drugs(MedPage Today) -- The FDA is requiring manufacturers of all GLP-1 drugs to update their prescribing information to include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding...
-
2d ago
FDA requires new safety warnings for GLP-1 drugsThe FDA is now requiring labeling updates for all GLP-1 medications due to a risk of NAION, a rare eye condition that can result in sudden, permanent vision loss.
-
2d agoFDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition
Today, the U.S. Food and Drug Administration (FDA) announced that patients and healthcare providers should be aware of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION…
-
2d ago
FDA to require NAION risk warning for GLP-1 therapiesEditor’s note: This is a developing news story. Please check back soon for updates. The FDA is requiring manufacturers of GLP-1 receptor agonist therapies to include warnings regarding the risk for nonarteritic anterior ischemic optic neuropathy, according to a drug safety communication. The agency…
-
2d ago
FDA warns of rare 'eye stroke' risk from GLP-1 drugsThe Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic…
-
1d agoSafety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trials
Background Oral glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been developed as a needle-free alternative of subcutaneous injectables GLP-1 RAs. This systematic review and meta-analysis evaluated whether oral GLP-1 receptor agonists improve body weight and metabolic outcomes, and…
-
1d agoFDA orders blindness risk warning to GLP-1 agonist labels
FDA orders blindness risk warning to GLP-1 agonist labels Phil.Taylor Tue, 10/11/2026 - 10:49
-
1d agoFDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
-
1d ago
STAT+: GLP-1s are given an FDA warning for rare eye condition riskWant to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news that we’ll get straight into. The need-to-know this morning Beam Therapeutics said its CRISPR-based treatment for sickle cell disease…
-
1d ago
'Ozempic made me go suddenly blind': Victim reveals devastation after losing his sight on the jabs as US health chiefs order new warning over 'eye stroke' vision loss riskIt was Christmas Day two years ago when Jay Vandegriff noticed a smudge on his glasses which obscured his left eye.
-
1d ago
USFDA Flags Potential Vision Loss Risk with Ozempic, Wegovy, Mounjaro, Seeks Label Warning UpdateBengaluru : The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. The US Food and Drug Administration said it is requiring GLP-1 drugs such as Eli Lilly's…
-
1d ago
FDA Initiates Labeling Changes for GLP-1s Due to Rare But Serious Eye Disease RiskA rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a…
-
1d agoFDA Mandates Label Updates for GLP-1 Receptor Agonists Over Eye Risk
A new safety communication highlights a potential increased risk of a rare but serious eye condition associated with a popular class of medications. Key takeaways: The FDA is requiring safety labeling changes for all GLP-1 receptor agonist medications to include warnings about a potential increased…
-
1d ago
FDA Requires GLP-1s to Carry Warning About Rare Risk of Vision LossThe U.S. Food and Drug Administration (FDA) announced this week that it is requiring manufacturers of all GLP-1 diabetes and obesity medications to make labeling changes that will warn patients about the increased risk of a rare eye condition linked to these…
-
1d ago
Rare eye condition prompts new FDA warning on popular GLP-1 drugsThe U.S. Food and Drug Administration (FDA) is requiring makers of Ozempic, Wegovy and similar drugs to warn of a rare eye condition that can cause vision loss.
-
1d ago
GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effectMillions of people worldwide take GLP-1 medications. Michael Siluk/Universal Images Group via Getty Images GLP-1 drugs must now carry a warning label about a potential link to a rare eye condition that can result in vision loss, the U.S. Food and Drug Administration announced on Nov. 9. 2026. The…
-
1d agoRare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide
Nature Metabolism, Published online: 11 November 2026; doi:10.1038/s42255-026-01656-z Rare GLP1R variants are shown to reduce weight loss with semaglutide but not tirzepatide, suggesting GLP1R genetic variation as a pharmacogenetic determinant of GLP-1 receptor agonist efficacy.
-
11h ago
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warningThe deal gives AstraZeneca a simpler way to make conjugate vaccines. Elsewhere, a psychedelic depression drug was submitted to the FDA and an autoimmune disease-focused biotech’s shares collapsed.
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.